Loading…
← CockpitCompetitor Analysis › 603205.SS Jianerkang Medical Co. Ltd. Class AOpen in the cockpit ↗

Jianerkang Medical Co. Ltd. Class A603205.SSCompetitor analysis, valuation and peers

China · CNY·Industrials›Miscellaneous Commercial Services
Momentum strong 69
Mkt cap
$487M
US dollars, full cap
$/day
$2.71M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+13.1 pp
WACC 5.1%
Hurdle
+6 pp
Req g minus delivered
Close · CNYCN¥21.15
1D-0.8%
1W+3.3%
1M-2.6%
3M+0.3%
6M-18.8%
YTD-26.0%
1Y-25.9%
ATR %2.9%
52w lowhigh31.9% off high

What Jianerkang Medical does

Employees: 1,694

Jianerkang Medical at a glance

Size Jianerkang Medical (603205.SS) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $487M, the 3917th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥21.15 on 6 Nov 2026.

Performance Over six months the shares fell 18.8%, against -5.4% for the median peer and -16.4% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue fell 2.0% over the last twelve months (peer median +5.5%); the operating margin is 13.7% (peer median 7.6%).

Valuation It trades at 2.3× enterprise value to sales against a peer median of 2.9× (9th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is -9%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 13.1 points above its cost of capital (5.1% WACC).

Relative performance

809010011 May 202611 Aug 20266 Nov 2026Peer median 94603205.SS 81
Six months, rebased to 100: Jianerkang Medical against the median of its 20 peers (local-currency closes).

Jianerkang Medical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.10BCN¥1.02BCN¥1.04BCN¥1.03BCN¥1.09B
Revenue growth—-2%+1%-5%—
Gross profitCN¥313MCN¥238MCN¥229MCN¥226MCN¥254M
EBITDAn/aCN¥169MCN¥165MCN¥132MCN¥148M
Net incomeCN¥123MCN¥111MCN¥120MCN¥124MCN¥157M
Free cash flowCN¥92.3MCN¥90.3MCN¥102MCN¥73.6MCN¥96.8M
Capital expenditureCN¥101MCN¥70.0MCN¥39.7MCN¥84.2MCN¥66.3M
Total debtCN¥18.0MCN¥21.8MCN¥0CN¥0CN¥30.0M

Quarterly statements and history in the cockpit →

Jianerkang Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%+10%GPI3636MAPMYINDIA77223010388771301259COOR300649688265001390MHAIEGDIV0799403008873008594480ADN1301449603205.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Jianerkang Medical is the large dot.

Fundamentals: revenue growth against valuation

-40%-20%0%+20%0×10×20×GPI3636MAPMYINDIA3010388771301259COOR300649688265MHADIV3008594480ADN1603205.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jianerkang Medical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%3636MAPMYINDIA3010388771COORMHAIEGDIV0799403008594480ADN1301449603205.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jianerkang Medical is the large dot.

Jianerkang Medical competitors and peer comparison

How Jianerkang Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jianerkang Medical against its 20 peers (data as of 6 Nov 2026)
Measure603205.SSPeer medianRank in peer set
1-month return-2.6%-2.1%11th highest of 21
6-month return-18.8%-5.4%7th lowest of 21
Distance from 52-week high-31.9%-26.4%10th lowest of 21
Revenue growth (TTM)-2.0%+5.5%4th lowest of 21
Operating margin13.7%7.6%9th highest of 21
EV / Sales2.3×2.9×9th cheapest of 20
Growth the price implies (Req g, 7 yrs)-2.9%2.1%6th least demanding of 14
Growth delivered (Del g)-8.8%+18.3%lowest of 14
Hurdle (Req g minus delivered)+5.9 pp-13.7 pp2nd most demanding of 14
ROIC minus cost of capital+13.1 pp+1.3 pp3rd highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Jianerkang Medical 603205.SSChina$487M-19%-2%14%2.3×-2.9%-8.8%
GPI GPI.MIItaly$487M-3%+2%6%1.6×n/an/a
Mitsubishi Research Institute 3636.TJapan$489M+8%+4%7%0.4×-9.9%+4.1%
C.E. Info Systems MAPMYINDIA.NSIndia$486M-13%+3%31%8.1×31.1%+25.5%
LINE Pay Taiwan 7722.TWTaiwan$484M-16%+20%6%n/an/an/a
Shenzhen Water Planning & Design Institute 301038.SZChina$484M-26%+6%8%3.2×20.2%-1.9%
eGuarantee 8771.TJapan$482M-5%+5%48%5.8×-6.7%+8.3%
Hunan Airbluer Environmental Protection Technology 301259.SZChina$498M-47%-43%-17%23.1×n/an/a
Coor Service Management COOR.STSweden$475M-16%-1%5%0.6×-8.2%+5.4%
Hangzhou Landscape Architecture Design Institute 300649.SZChina$473M+24%-24%-39%24.6×n/an/a
Shanghai Model Organisms Center 688265.SSChina$503M+7%+14%-1%5.5×n/an/a
Anhui Guqi Down and Feather Textile 001390.SZChina$472M-26%+9%16%3.1×n/an/a
MHA MHA.LUnited Kingdom$504M-4%+12%15%1.5×-15.0%+30.6%
Italian Exhibition IEG.MIItaly$505M+14%+4%18%2.1×-4.8%+28.4%
Diversified Royalty DIV.TOCanada$507M-6%+15%86%17.9×13.0%+18.3%
Gabia 079940.KSSouth Korea$468M+64%+12%14%2.6×1.0%+14.7%
Pony Testing 300887.SZChina$513M-35%-2%-12%2.1×n/an/a
Western Regions Tourism Development 300859.SZChina$513M-30%-13%15%12.0×38.8%+44.7%
Medley 4480.TJapan$463M+2%+24%8%1.9×16.0%+40.0%
adesso ADN1.DEGermany$513M+31%+13%4%0.5×2.1%+22.9%
Shenzhen Tiansu Calibration & Testing 301449.SZChina$462M-30%+8%10%2.9×11.1%+13.2%

Questions

Which companies are Jianerkang Medical's closest peers?
The cockpit's peer set: GPI (GPI.MI), Mitsubishi Research Institute (3636.T), C.E. Info Systems (MAPMYINDIA.NS), LINE Pay Taiwan (7722.TW), Shenzhen Water Planning & Design Institute (301038.SZ), eGuarantee (8771.T), Hunan Airbluer Environmental Protection Technology (301259.SZ), Coor Service Management (COOR.ST).
Is Jianerkang Medical expensive compared with its peers?
On ev / sales it trades at 2.3× against a peer median of 2.9×, 9th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is -9%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Jianerkang Medical stock performed?
Over six months to 6 Nov 2026 the shares returned -18.8% against -5.4% for the median peer; over one year -25.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.